CHE

Chemed Corp

Add to Watchlist

Advanced Chart

574.960

+9.100(+1.610%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

582.890

Open

563.030

VWAP

575.60

Vol

150.87K

Mkt Cap

8.41B

Low

563.030

Amount

86.84M

EV/EBITDA(TTM)

16.63

Total Shares

15.08M

7.95B

EV/OCF(TTM)

21.73

P/S(TTM)

3.36

Chemed Corporation is engaged in purchasing, operating, and divesting subsidiaries in diverse business activities. The Company operates through two segments: VITAS and the Roto-Rooter. VITAS segment provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers. It provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Roto-Rooter provides plumbing, drain cleaning and water restoration services to both residential and commercial customers. Roto-Rooter segment provides plumbing, drain cleaning, excavation, water restoration and other related services to residential and commercial customers. The Roto-Rooter services are provided through a network of Company-owned branches, independent contractors and franchisees. Its Water Restoration Services involve the remediation of water and humidity after a flood.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

679.99M

+6.25%

7.360

+7.76%

655.71M

+8.17%

6.200

+9.93%

649.66M

+9.03%

6.020

+10.05%

Estimates Revision

The market is revising Upward the revenue expectations for Chemed Corporation (CHE) for FY2025, with the revenue forecasts being adjusted by 2.09% over the past three months. During the same period, the stock price has changed by 3.09%.

Revenue Estimates for FY2025

Revise Upward

+2.09%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+2.23%

In Past 3 Month

Stock Price

Go Up

+3.09%

In Past 3 Month

2 Analyst Rating

19.57% Upside

Wall Street analysts forecast CHE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CHE is 687.50 USD with a low forecast of 667.00 USD and a high forecast of 708.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

19.57% Upside

Current: 574.960

Low

667.00

Averages

687.50

High

708.00

19.57% Upside

Current: 574.960

Low

667.00

Averages

687.50

High

708.00

RBC Capital

Ben Hendrix

Buy

Maintains

$667 → $674

2025-04-28

New

Reason

RBC Capital

Ben Hendrix

Price Target

$667 → $674

2025-04-28

New

Maintains

Buy

Reason

RBC Capital analyst Ben Hendrix raised the firm's price target on Chemed to $674 from $667 and keeps an Outperform rating on the shares after its Q1 earnings beat. The firm remains positive on the stock following a "solid" Q1 report and given an improved outlook for Roto-Rooter, the analyst tells investors in a research note. Concerns over potential Medicare cap limitations are overblown with the company proactively managing with shorter-stay hospital admissions in select markets, RBC adds.

RBC Capital

Ben Hendrix

Buy

Maintains

$633 → $667

2025-03-14

Reason

RBC Capital

Ben Hendrix

Price Target

$633 → $667

2025-03-14

Maintains

Buy

Reason

RBC Capital raised the firm's price target on Chemed to $667 from $633 and keeps an Outperform rating on the shares after its Q4 earnings beat last month. Chemed expects VITAS ADC momentum to continue in 2025 with the outlook calling for 8.5%-9.0% growth, and the firm is encouraged that Roto-Rooter appears to be normalizing after several quarters of declining revenue, the analyst tells investors in a research note. RBC adds that the company expects modest commercial demand recovery this year for Roto-Rooter leading to low-single-digit growth.

RBC Capital

Ben Hendrix

Buy

Maintains

$697 → $633

2024-11-05

Reason

RBC Capital

Ben Hendrix

Price Target

$697 → $633

2024-11-05

Maintains

Buy

Reason

RBC Capital lowered the firm's price target on Chemed to $633 from $697 and keeps an Outperform rating on the shares after its Q3 earnings. The company delivered solid results with VITAS strength largely offsetting continued Roto-Rooter headwinds, and the firm was also encouraged to see census momentum continue, bolstered by strong hiring, the analyst tells investors in a research note. RBC adds however that its price target cut reflects a roll in its valuation model to next year's estimates.

RBC Capital

Ben Hendrix

Buy

Maintains

$712 → $697

2024-05-21

Reason

RBC Capital

Ben Hendrix

Price Target

$712 → $697

2024-05-21

Maintains

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Chemed Corp (CHE.N) is 21.43, compared to its 5-year average forward P/E of 25.10. For a more detailed relative valuation and DCF analysis to assess Chemed Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

25.10

Current PE

21.43

Overvalued PE

27.06

Undervalued PE

23.14

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

16.85

Current EV/EBITDA

14.93

Overvalued EV/EBITDA

18.01

Undervalued EV/EBITDA

15.69

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

3.44

Current PS

3.03

Overvalued PS

3.65

Undervalued PS

3.23